Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease

Gut

Volumn 38, Issue 1, 1996, Pages 99-103

  Mahmud, N ^a   McDonald, G S A ^a   Kelleher, D ^a   Weir, D G ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Crohn's disease; Disease activity; Inflammatory bowel disease; Intestinal histopathological grading; Microalbuminuria; Ulcerative colitis

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENDOSCOPY; ENTERITIS; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0030048257     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.1.99     Document Type: Article

References (26)

1. Beck IT. Laboratory assessment of IBD. Dig Dis Sci 1987; 32 (suppl): 26-41.
2. Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid-A protein compared with C-reactive protein α1-antichymotrypsin and α1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest 1987; 17: 460-4.
3. Becken WL, Busch HJ, Sylwester DL. Intestinal protein loss in Crohn's disease. Gastroenterology 1972; 62: 207-15.
4. von Tongeren JH, Eekhout A. Criteria to assess the severity of Crohn's disease and effect of treatment. In: Weterman IT, Pena AS, Booth CC, eds. The management of Crohn's disease. Proceedings of the Workshop on Crohn's disease. Leyden 23-25 October 1975. Amsterdam: Elsevier, 1976: 153-8.
5. Saverymuttu SH, Camerilli M, Rees H, Lavender JP, Hodgson HJF, Chadwick VS. Indium-111 granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. Gastroenterology 1986; 90: 1121-8.
6. Stein DT, Gray GM, Gregory PB, Anderson M, Goodwin DA, McDougall IR. Location and activity of ulcerativc colitis and Crohn's colitis by Indium-111 leucocyte scan. Gastroenterology 1983; 84: 388-93.
7. Saverymuttu SH, Peters AM, Lavender JP, Hodgson HJF, Chadwick VS. Quantitative faecal Indium-111 labelled leucocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology 1983; 85: 1333-9.
8. Gosling P, Shearman CP. Increased levels of urinary proteins: marker of vascular permeability? Ann Clin Biochem 1988; 25 (suppl): 150-1.
9. Gosling P, Sutcliffe AJ, Cooper MACS, Jones AF. Burns and trauma associated proteinuria: role of lipid peroxidation, renin and myoglobin. Ann Clin Biochem 1988; 296: 1295-8.
10. Mahmud N, Stinson J, O'Connell M, Mantle T, Keeling PWN, Feely J, et al. Microalbuminuria in patients with inflammatory bowel disease. Gut 1994; 35: 1599-604.
11. Harvey RF, Bradshaw JW. A simple index of Crohn's disease activity. Lancet 1980; i: 514.
12. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne J-F, et al. Correlation between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut 1994; 35: 231-5.
13. Gomes P, Boulay Claire Du, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92-5.
14. Park RHR, McKillop JH, Duncan A, MacKenzie JF, Russell RI. Can Indium-111 autologous mixed leucocyte scanning accurately assess disease extent and activity in Crohn's disease? Gut 1988; 29: 821-5.
15. Best WR, Becklet JM, Singleton JW, Kern F. Development of a Crohn's disease activity index: National Co-operative Crohn's disease study, Gastroenterology 1976; 70: 439-44.
16. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79: 319-26.
17. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentration of TNFa in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
18. Nakamura M, Saito H, Kananuki J, Tamura Y, Yoshida S. Cytokine production in patients with inflammatory bowel disease. Gut 1992; 33: 933-7.
19. Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A, et al. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 1991; 50: 104-11.
20. Murch SH, MacDonald TT, Walter-Smith JA, Levin M, Lionetti P, Klein NJ. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 1993; 341: 711-4.
21. Rosenzweig LJ, Kanwar YS. Removal of sulphated (heparan sulphate) and non-sulphated (hyaluronic acid) results in increased permeability of the glomerulus basement membrane to 125I-bovine serum albumin. Lab Invest 1982; 47: 177-84.
22. Kanwar YS, Linker A, Farquar MG. Increased permeability of glomeruluar basement membrane to ferritin after removal of glycosaminoglycans (heparan sulphate) by enzymatic digestion. J Cell Biol 1980; 86: 688-94.
23. Vehaskari VM, Chang CT-C, Stevens JK, Robson AM. The effects of polycations on vascular permeability in the rats. J Clin Invest 1984; 84: 1053-9.
24. Klein NJ, Shenan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 1992; 102: 821-32.
25. Yi ES, Ulich TR. Endotoxin, interleukin-1, and tumour necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol 1992; 140: 659-63.
26. Mahmud N, O'Connell MA, Stinson J, Goggins MG, Weir DG, Kelleher D. Tumour necrosis factor-α and microalbuminuria in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology 1995; 7: 215-9.